|Awarded On||February 18, 2015|
|Title||Developing New Combinatory Therapies for Pediatric High Grade Glioma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Xiao-Nan Li|
|Cancer Sites||Brain and Other Nervous System|
The five year survival in children with high grade glioma is still less than 10%. Recent advances of genomic sequencing methods have made it possible to discover nearly all gene mutations in pediatric gliomas. The objective of this application is therefore to develop new combinatory therapies that will selectively target those mutations critical for tumor cell survival. Since most of the tumors have many different mutated genes, we have designed a new “anchor-probe” strategy to selectively and efficiently target multiple abnormalities. Based on the genetic concept known as “synthetic lethality”, we hypothesize that simultaneous perturbation of two (or more) mutated genes can result in a dead...